AbbVie Inc (NYSE:ABBV) on 09/07/2018 declared a dividend of $ 0.9600 per share payable on November 15, 2018 to shareholders of record as of October 15, 2018.

AbbVie Inc (NYSE:ABBV) has paid dividends since 2013, has a current dividend yield of 4.10% and has increased its dividends for 4 successive years.

AbbVie Inc's market cap is $ 141,947,951,020 and has a PE ratio of 23.20. The stock price closed yesterday at $ 93.74 and has a 52 week low/high of $ 77.00 and $ 125.86.

AbbVie is a research-based biopharmaceutical company. Co.'s portfolio of products includes a line of therapies that addresses serious diseases such as: HUMIRA (adalimumab) to treat autoimmune diseases; oncology products such as IMBRUVICA (ibrutinib) and Venclexta (venetoclax); virology products such as VIEKIRA PAK for the treatment of hepatitis C and Norvir (ritonavir) for the treatment of human immunodeficiency virus-1 infection; metabolic and hormone products that target conditions such as testosterone deficiency; endocrinology products such as Lupron (leuprolide acetate) for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty.

For more information on AbbVie Inc click here.